Overview
What is Wegovy?
Wegovy is a once-weekly injectable medication FDA-approved specifically for chronic weight management in adults and adolescents (12+) with obesity or overweight with at least one weight-related condition. It contains the same active ingredient as Ozempic — semaglutide — but at a higher target dose (2.4 mg/week vs Ozempic's 2 mg ceiling).
How it works
Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone released after meals, dramatically reducing appetite, slowing gastric emptying, and increasing satiety. Patients typically eat 30-40% fewer calories without willpower. In the STEP-1 trial, average weight loss at 68 weeks was 14.9% of body weight.
Who it's for
FDA-approved for adults with BMI ≥ 30 (obesity), or BMI ≥ 27 (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or high cholesterol. Also approved for adolescents 12+ with BMI in the 95th percentile or above. Not for pregnancy or family history of medullary thyroid carcinoma.
Side effects & nutritional management
The two most common — each row gives the typical frequency and the specific nutrition strategy that helps most patients manage it.
Nausea
Very commonThe fix
Eat 5–6 small, room-temperature meals. Avoid fried, fatty, spicy foods. Ginger tea or capsules pre-meal. Stop eating at first sign of fullness — Wegovy delays gastric emptying.
Reported by 44% of patients against 16% on placebo (prescribing information, section 6.1) — the highest rate of any GLP-1 in this set. Most intense during the 16-week titration, typically peaking 24-48 hours after an injection.
Diarrhea
CommonThe fix
BRAT-style foods (banana, rice, applesauce, toast) plus electrolyte drinks. Avoid sugar alcohols, dairy if lactose-sensitive. Reintroduce regular foods slowly.
Reported by 30% versus 16% on placebo in the label's trials, often around a dose escalation.
Nutrition strategy
Daily targets, foods to emphasize, foods to avoid — adapted to Wegovy specifically.
Protein target
1.4–1.6 g per kg per day during maintenance dose. Slightly lower (1.2–1.4 g/kg) during titration if nausea is severe. Spread across 3–4 meals; afternoon snack is critical.
Hydration
2.5–3 L water daily. Sip throughout, not in large gulps with meals. Wegovy's longer half-life means slower emptying; large fluid volumes during meals worsen reflux and fullness.
Meal timing
Front-load calories at breakfast and lunch when appetite is strongest. Plan a 4th eating occasion (3–4 PM) — most patients drop protein significantly by skipping this. Time meals away from injection day if nausea is dose-related.
Foods to emphasize
- Lean proteins: chicken, white fish, eggs, Greek yogurt, lentils, tempeh
- Soluble fiber: oats, chia, psyllium husk, berries, apples
- Hydrating produce: cucumber, watermelon, leafy greens
- Anti-inflammatory fats (moderation): avocado, olive oil, walnuts
- Easy-digest complex carbs: quinoa, sweet potato, banana, oatmeal
Foods to avoid
- Fried foods (worsen nausea, slow emptying further)
- Sugar alcohols (xylitol, sorbitol — cause GI distress)
- High-fat dairy and creamy sauces
- Alcohol (compounds nausea, hypoglycemia, dehydration)
- Refined sugars and ultra-processed foods (cause blood sugar spikes)
Phase-by-phase strategy
Your nutrition plan should adapt as your body and dose change. Here's what matters at each phase of Wegovy treatment.
01Titration (weeks 1–16)
16 weeks; dose escalates 0.25 → 0.5 → 1 → 1.7 → 2.4 mg
Titration (weeks 1–16)
16 weeks; dose escalates 0.25 → 0.5 → 1 → 1.7 → 2.4 mg
Tolerance building and side-effect management
- Each dose escalation can re-trigger nausea — re-introduce small meal strategy
- Protein 1.2–1.4 g/kg, leaning on liquid protein when severe nausea
- Daily hydration tracking — start now
- Begin gentle resistance training (bodyweight) by week 8 if energy allows
02Active weight loss (months 5–14)
9–10 months at maintenance dose 2.4 mg
Active weight loss (months 5–14)
9–10 months at maintenance dose 2.4 mg
Sustained loss with active muscle preservation
- Push protein to 1.4–1.6 g/kg consistently
- Resistance training 3x/week — non-negotiable; progressive overload
- Body composition tracking monthly (smart scale, ideally DEXA every 3 months)
- Average weight loss 12–15% by month 14
03Long-term maintenance (year 2+)
Ongoing — many patients stay on Wegovy indefinitely
Long-term maintenance (year 2+)
Ongoing — many patients stay on Wegovy indefinitely
Sustainability and metabolic health
- Continue 1.4–1.6 g/kg protein target
- Strength training maintained as primary anti-aging strategy
- Annual labs: B12, vitamin D, iron, thyroid, lipid, A1c
- Monitor for plateau; dose adjustment requires physician review
04Tapering off Wegovy
If discontinuing — over 12–16 weeks per physician guidance
Tapering off Wegovy
If discontinuing — over 12–16 weeks per physician guidance
Rebound prevention
- Regain after stopping: ~60% of lost weight by 52 weeks, levelling off near 75% (Budini 2026 meta-regression)
- Increase protein further as appetite returns
- Maintain training schedule from maintenance phase
- Weekly weigh-ins (not daily); body comp monthly
How MALAI helps
We do this math, for you, every day.
Phase-aware meal plans, side-effect protocols, and protein architecture — all adapted to your Wegovy dose and treatment week.
Get startedFurther reading
Research and protocols that apply to Wegovy.
How much protein do you need on a GLP-1? What the clinical trials actually show
The 'up to 40%' muscle-loss number gets repeated everywhere, but the real research shows a much wider range — 15% to 60% depending on the study. Here's what actually predicts where you land, with the trial data.
Read it →How to protect muscle while losing weight on GLP-1s: a 4-week protein protocol
Lean tissue is 15% to 60% of the weight lost on a GLP-1, depending on the study. This 4-week protein protocol — adapted to your medication, dose and titration phase — gives you the daily targets, meal templates and progress checks that protect strength while you lose fat.
Read it →Frequently asked questions
Common questions from people taking Wegovy.
- How much weight will I lose on Wegovy?
- STEP-1 trial: average 14.9% of body weight loss at 68 weeks at the 2.4 mg dose, paired with lifestyle counseling. Real-world results vary — 5–20% is the typical range. Adherence to protein intake and resistance training are major variables in long-term outcomes.
- Is Wegovy covered by insurance?
- Coverage varies dramatically. Many plans cover Wegovy when prescribed for FDA-approved indications (BMI ≥ 30 or ≥ 27 with comorbidity), but many require prior authorization. Cash price is ~$1,350/month. Check with your insurer; manufacturer coupons can offset cost in some cases.
- How long do I need to stay on Wegovy?
- Most prescribers treat it as ongoing rather than a course you finish. A 2026 meta-regression in eClinicalMedicine pooling six randomised trials found about 60% of the weight lost comes back within 52 weeks of stopping, levelling off near 75% longer term. That is why it is usually framed like blood-pressure medication — continued unless side effects or circumstances force a change.
- What's the difference between Wegovy and Ozempic?
- Same active ingredient (semaglutide), different doses and FDA indications. Wegovy: up to 2.4 mg/week, FDA-approved for weight management. Ozempic: up to 2 mg/week, FDA-approved for type 2 diabetes (often prescribed off-label for weight).
- Can I take Wegovy and Mounjaro together?
- No. They're both GLP-1 receptor agonists (Wegovy = semaglutide; Mounjaro = tirzepatide, which adds GIP). Combining them isn't recommended — switching from one to the other requires a washout period and physician guidance.
- Why is muscle preservation so important on Wegovy?
- Wegovy runs to a 2.4mg maintenance dose and is designed for long-term use, so whatever body-composition pattern you establish, you establish it for years rather than months. Trial evidence collected in Neeland 2024 puts lean tissue anywhere between 15% and 60% of total weight lost. Sustained protein intake and resistance training are what decide where in that band you sit.
- Does Wegovy need more protein than Ozempic?
- Same molecule, higher ceiling, so in practice yes. Wegovy titrates across 16 weeks to 2.4mg against Ozempic's 2mg, and it is designed for indefinite use rather than glycaemic control. The guidance here is 1.4–1.6g per kg at maintenance, easing to 1.2–1.4g during titration if nausea is severe — a narrower, higher band than the 1.2–1.6g used for Ozempic. Both bands sit inside the 1.2–1.6g/kg that the 2025 joint advisory proposed during active weight reduction.
Disclaimer. MALAI is not a medical provider. Always consult your physician before making changes to your treatment plan. The information on this page is for educational purposes only and is not a substitute for medical advice. Wegovy is a prescription medication; only your physician can determine whether it's appropriate for you, what dose to use, and how to manage side effects safely.